Relevant Publications

Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV. (2008) An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320: 226-30.

Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P, Bellnier B, Krivokrysenko VI, Feinstein E, Gudkov AV. (2012) Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Rad Oncology Biol Physics, 83(1):228-34.

Yoon S-I, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA. (2012) Structural Basis of TLR5-Flagellin Recognition and Signaling. Science. 335(6070):859-64.

Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova K, Gleiberman AS, Aygun-Sunar S, Veith J, Johnson C, Haderski GJ, Stanhope-Baker P, Allamaneni S, Skitzki J, Zeng M, Martsen E, Medvedev A, Scheblyakov D, Artemicheva NM, Logunov DY, Gintsburg AL, Naroditsky BS, Makarov SS, Gudkov AV. (2013) Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonists. PNAS 110(20):E1857-66.

Tukhvatulin AI, Gitlin II, Shcheblyakov DV, Artemicheva NM, Burdelya LG, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL, Logunov DY. (2013) Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-kB, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection. Infect Immun. 81(10):3855-64.

Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG, Gudkov AV, Cao X. (2014) A flagellin- derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS One. 9(1):e85587.

Kojouharov BM, Brackett CM, Veith JM, Johnson CP, Gitlin II, Toshkov IA, Gleiberman IS, Gudkov AV, Burdelya LG. (2014) Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5- fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget 5(3):802-814.

 Krivokrysenko VI, Toshkov I, Gleiberman AS, Krasnov P, Shyshynova I, Bespalov I, Maitra R, Narizhneva N, Singh VK, Whitnall M, Purmal A, Shakhov A, Gudkov AV, Feinstein E. (2015) The TLR5 Agonist Entolimod Mitigates Acute Radiation Syndrome in Non-human Primates. PLoS One. 10(9):e0135388.

Yang H, Brackett CM, Morales-Tirado VM, Li Z, Zhang Q, Wilson MW, Benjamin C, Harris W, Waller EK, Gudkov AV, Burdelya LG, Grossniklaus HE. (2016) The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget. 7(3):2936-50.

Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. (2016) Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. PNAS Feb 16;113(7): E874-883.

Toshkov IA, Gleiberman AS, Mett VL, Hutson AD, Singh AK, Gudkov AV, Burdelya LG. (2017) Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation. Radiat Res. 187(5):570-80.

Mett V, Komarova EA, Greene K, Bespalov I, Brackett C, Gillard B, Gleiberman AS, Toshkov IA, Aygün-Sunar S, Johnson C, Karasik E, Bapardekar-Nair M, Kurnasov OV, Osterman AL, Stanhope-Baker PS, Morrison C, Moser MT, Foster BA, Gudkov AV. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37(4):439-49.

Haderski GJ, Kandar BM, Brackett CM, Toshkov IM, Johnson CP, Paszkiewicz GM, Natarajan V, Gleiberman AS, Gudkov AV, Burdelya LG. (2020). TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. PLoS One. 15(2): e0227940.

Eremina NV, Kazey VI, Mishugin SV, Leonenkov RV, Pushkar DY, Mett VL, and Gudkov AV. (2020). First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. Oncotarget. 11(14): 1273-1288.

Singh VK, Seed TM. Entolimod as a radiation countermeasure for acute radiation syndrome. Drug Discov Today. 2021 Jan; 26(1): 17-30.

Mett V, Kurnasov OV, Bespalov IA, Molodtsov I, Brackett CM, Burdelya LG, Purmal AA, Gleiberman AS, Toshkov IA, Burkhart CA, Kogan YN, Andrianova EL, Gudkov AV, Osterman AL. A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications. (2021). Commun Biol, Apr 12;4(1):466.

Brackett CM, Greene KF, Aldrich AR, Trageser NH, Pal S, Molodtsov I, Kandar BM, Burdelya LG, Abrams SI and Gudkov AV. Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9. (2021). Cell Death Discovery, Sep 28;7(1):266.

Kosten TR, Domingo CB, Haile CN, Nielsen DA. (2022), A Clinical Trial of Entolimod a TLR-5 Adjuvant for Vaccines Using Diphtheria or Tetanus as Carrier Proteins. Vaccines (Basel). 2022.10(10):1592.